公开(公告)号：US10351500B2

公开(公告)日：2019-07-16

申请号：US16030854

申请日：2018-07-09

申请人： Hong Kong Baptist University

发明人： Hongjie Zhang ,  Siu Wai Tsang

IPC分类号： C07C43/23 ,  C07C39/16 ,  C07C37/00 ,  C07C43/215 ,  C07C39/21 ,  A61Q17/04 ,  C07C69/753 ,  C07C69/34 ,  A61Q19/02 ,  C07C69/736 ,  A61K31/05 ,  C07C43/205 ,  A61K8/33 ,  A61K8/37 ,  A61K8/34 ,  A61K31/085 ,  A61K31/09 ,  A61K9/00 ,  C07C39/15 ,  A61Q17/00 ,  C07C69/30 ,  C07C69/616 ,  C07C69/712 ,  C07C69/74 ,  C07C69/76 ,  C07C69/78 ,  C07C69/92

摘要： The present invention relates to a composition for preventing or reducing microbial growth, particularly the growth of dermatophytic fungi, and/or aciduric and acidogenic gram-positive bacteria. More particularly, it relates to the use of trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, or its dihydrostilbene derivatives and/or chemical variants as an anti-microbial agent. The present invention further relates to the management of dermatophytosis often caused by dermatophytic fungi and the management of dental caries often mediated by aciduric and acidogenic gram-positive Streptococci. The present invention therefore has applications in preventing, alleviating and/or treating dermatophytosis and dental caries.

公开(公告)号：US20190183833A1

公开(公告)日：2019-06-20

申请号：US15842807

申请日：2017-12-14

申请人： NMD Pharma ApS

发明人： Lars J.S. Knutsen ,  Thomas Holm Pedersen ,  Martin Broch-Lipps ,  Claus Elsborg Olesen ,  Marc Labelle ,  Ole Bækgaard Nielsen

IPC分类号： A61K31/216 ,  A61K31/085 ,  A61K31/055 ,  A61P21/04

CPC分类号： A61K31/216 ,  A61K31/055 ,  A61K31/085 ,  A61P21/04 ,  C07K14/70571

摘要： The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

公开(公告)号：US20190175675A1

公开(公告)日：2019-06-13

申请号：US16257389

申请日：2019-01-25

申请人： Ronald D. SEKURA ,  Roscoe M. MOORE

发明人： Ronald D. SEKURA ,  Roscoe M. MOORE

IPC分类号： A61K36/185 ,  A61K31/05 ,  A61K8/49 ,  A61K31/045 ,  A61K9/08 ,  A61K9/06 ,  A61K9/00 ,  A61K31/085 ,  A61K31/12 ,  A61K31/235 ,  A61K31/245 ,  A61K31/352 ,  A61K31/573 ,  A61K31/618 ,  A61K36/00 ,  A61K36/61 ,  A61K45/06 ,  A61K47/12 ,  A61K47/44 ,  A61P17/06 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q19/00 ,  A61K31/047

摘要： A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.

公开(公告)号：US20190151232A1

公开(公告)日：2019-05-23

申请号：US16198793

申请日：2018-11-22

申请人： David SCHARP

发明人： David SCHARP

IPC分类号： A61K9/00 ,  A61K31/78 ,  A61K31/015 ,  A61K36/185 ,  A61K47/20 ,  A61K31/047 ,  A61K36/71 ,  A61K36/886 ,  A61K38/39 ,  A61K31/685 ,  A61K47/08 ,  A61K47/44 ,  A61K47/46 ,  A61K31/192 ,  A61K31/245 ,  A61K47/26 ,  A61K31/355 ,  A61K31/197 ,  A61K31/4172 ,  A61K31/085 ,  B01F3/08 ,  B01F7/00 ,  B01F15/06

摘要： Compositions for the treatment of some orphan diseases and oral mucosal ulcers, many with similarities in terms of their anti-inflammatory and anti-oxidative activities, but also multiple differences in their observed abilities that can be combined to challenge the current, underlying pathophysiology. The orphan diseases of interest are Dupuytren's Contracture, Peyronie's Disease, Scleroderma, Raynaud's (or Renaud's) Phenomenon, chemotherapy/radiation induced oral mucosal ulceration, and aphthous ulcers; and more frequent skin issues of skin damage from cuts, abrasions, and burns; aging skin changes, and toe nail fungus. These can be treated with the disclosed compositions with the proper combination and alteration of ingredients:

公开(公告)号：US10279005B2

公开(公告)日：2019-05-07

申请号：US14949352

申请日：2015-11-23

申请人： Allergan, Inc.

发明人： Anuradha V. Gore ,  Jaya Giyanani ,  Sukhon Likitlersuang

IPC分类号： A61K36/55 ,  A61K9/00 ,  A61K31/085 ,  A61K31/05

摘要： Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.

公开(公告)号：US20190083561A1

公开(公告)日：2019-03-21

申请号：US15521212

申请日：2015-10-21

申请人： Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG

发明人： Matthias H. Kreuter ,  Michael Kemmler

IPC分类号： A61K36/324 ,  A61K8/35 ,  A61K8/31 ,  A61Q19/00 ,  A23L2/52 ,  A61K8/33 ,  A61K31/015 ,  A61K31/085 ,  A23L33/105 ,  A61K31/045 ,  A61K8/9789 ,  A61K8/34 ,  A61K31/122

摘要： The invention relates to a novel extract from the resin of a plant of the genus Boswellia (Burseraceae). The invention further relates to a composition comprising the novel extract, in particular a pharmaceutical composition or a cosmetic composition, or a food supplement, a food or a beverage comprising the extract. Further, the invention concerns the use of the extract and the respective compositions, in particular the use of the extract or a composition comprising the extract in the cosmetic or therapeutic field as well as in food supplements. The invention also relates to the novel extract and the respective compositions for use in the treatment and/or prevention of a disease. A method of treatment and/or prevention of a neurodegenerative disease is further provided. A process is also provided, by which the novel extract is obtained.

公开(公告)号：US20190015355A1

公开(公告)日：2019-01-17

申请号：US16068251

申请日：2017-01-06

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Hasan Orhan AKMAN ,  Salvatore DIMAURO ,  Or KAKHLON

IPC分类号： A61K31/085 ,  A61K9/00 ,  G01N33/53 ,  A61P3/08

摘要： The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.

公开(公告)号：US20190008845A1

公开(公告)日：2019-01-10

申请号：US16067058

申请日：2016-12-13

申请人： Sharon ANAVI-GOFFER

发明人： Arquimedes Martinez Canedo

IPC分类号： A61K31/4535 ,  A61K31/085 ,  A61K31/225 ,  A61K31/352 ,  A61K31/16 ,  A61K31/047 ,  A61K31/09 ,  A61K47/14 ,  A61K47/44 ,  A61K47/10 ,  A61K47/26 ,  A61K47/24 ,  A61K47/22 ,  A61K9/00 ,  C12Q1/6876 ,  A61K31/4709 ,  A61K31/138 ,  A61K31/454

CPC分类号： A61K31/4535 ,  A61K9/0019 ,  A61K9/0085 ,  A61K31/047 ,  A61K31/085 ,  A61K31/09 ,  A61K31/138 ,  A61K31/16 ,  A61K31/225 ,  A61K31/352 ,  A61K31/454 ,  A61K31/4709 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44 ,  C12Q1/6876 ,  C12Q2600/106 ,  G05B19/056 ,  G05B2219/13019 ,  G05B2219/13022 ,  G06F21/14 ,  G06F21/76

摘要： The present invention provides a method of treatment of a neuropsychiatric disorder characterized by repetitive phenotype, comprising administering to a human or non-human subject in need thereof a therapeutically effective dose of a pharmaceutical composition comprising at least one active agent selected from a group of active agents comprising CB2 receptor inverse agonists and mixed CB2/SERM ligands. The present invention further provides pharmaceutical compositions comprising 4′-0-methylhonokiol, raloxifene, and their derivatives, HU-308 and/or BCP.

公开(公告)号：US20180360828A9

公开(公告)日：2018-12-20

申请号：US15884044

申请日：2018-01-30

申请人： Aquinox Pharmaceuticals (Canada) Inc.

发明人： Lloyd F. Mackenzie ,  Thomas B. MacRury ,  Curtis Harwig ,  David Bogucki ,  Jeffery R. Raymond ,  Jeremy D. Pettigrew ,  Vladimir Khlebnikov ,  Rudong Shan

IPC分类号： A61K31/4965 ,  A61K31/496 ,  A61K31/444 ,  A61K31/443 ,  A61K31/10 ,  A61K31/4465 ,  A61K31/4406 ,  A61K31/155 ,  A61K31/495 ,  A61K31/4196 ,  A61K31/4164 ,  A61K31/4402 ,  A61K31/166 ,  A61K31/095 ,  A61K31/277 ,  A61K31/165 ,  A61K31/167 ,  A61K31/09 ,  A61K31/192 ,  A61K31/05 ,  A61K31/085 ,  A61K31/135 ,  A61K31/122 ,  A61K31/12 ,  A61K31/4439

CPC分类号： A61K31/4965 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09 ,  A61K31/095 ,  A61K31/10 ,  A61K31/12 ,  A61K31/122 ,  A61K31/135 ,  A61K31/155 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/192 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/496 ,  C07B2200/07 ,  C07C39/17 ,  C07C43/21 ,  C07C43/215 ,  C07C43/23 ,  C07C49/83 ,  C07C49/835 ,  C07C49/84 ,  C07C62/32 ,  C07C62/34 ,  C07C217/84 ,  C07C225/20 ,  C07C233/26 ,  C07C233/28 ,  C07C233/31 ,  C07C233/32 ,  C07C233/60 ,  C07C233/76 ,  C07C235/82 ,  C07C237/08 ,  C07C255/47 ,  C07C275/26 ,  C07C275/64 ,  C07C279/16 ,  C07C311/07 ,  C07C311/17 ,  C07C311/18 ,  C07C317/22 ,  C07C323/20 ,  C07C2602/28 ,  C07D211/66 ,  C07D213/38 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/89 ,  C07D233/64 ,  C07D241/24 ,  C07D249/08 ,  C07D295/112 ,  C07D295/215 ,  C07D401/12 ,  C07D405/12

摘要： Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

公开(公告)号：US10098852B2

公开(公告)日：2018-10-16

申请号：US15521540

申请日：2015-10-23

申请人： LAUNX BIOMEDICAL CO., LTD.

发明人： Chiu-Hung Chen ,  Show-Mei Chuang ,  Tzong-Der Way ,  Nai-Wan Hsiao

IPC分类号： A01N31/14 ,  A61K31/075 ,  A61K31/085

摘要： A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Monobenzone or a pharmaceutical acceptable salt thereof. The cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, and skin cancer. The pleural-related cancer is lung cancer. The abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer. The endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer. The gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.